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Abstract
Background: Antibodies against programmed death 1 (PD-1) receptor and cytotoxic T-lymphocyte-associated
antigen 4 (CTLA-4) have transformed the systemic treatment of melanoma and many other cancers. Understanding
the spectrum of benign findings and atypical response patterns seen in immune checkpoint blockade is important
for accurately assessing treatment response as these immunotherapies become more widely used.
Case presentation: We report a 63-year-old man with metastatic melanoma successfully treated with combination
CTLA-4 and PD-1 blockade (ipilimumab and nivolumab), after non-response to pembrolizumab monotherapy. The
initial impression of disease progression, based on cutaneous and PET/CT findings of increased fluoro-2-deoxy-D-
glucose (FDG) uptake in benign lymphoid tissue, proved to be erroneous after assiduous review of radiographic
imaging and correlative pathology.
Conclusions: These findings indicate that increased FDG uptake in benign lymphoid tissue seen on PET/CT may
be a surrogate marker of immune activation and treatment response. Prospective studies will be invaluable in
validating immune-related radiographic findings as a prognostic biomarker of response in cancer patients being
treated with immune checkpoint blockade.
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Abbreviations: CT, Computed tomography; CTLA-4, Cytotoxic T-lymphocyte-associated antigen 4; FDG, Fluoro-
2-deoxy-D-glucose; irRC, Immune related response criteria; PD-1, Programmed death receptor-1; PET, Positron
emission tomography; RECIST, Response evaluation criteria in solid tumors; SLNB, Sentinel lymph node biopsy;
SUV, Standardized uptake value; WLE, Wide local excision
Background
Melanoma is an aggressive cutaneous neoplasm. Surgical
resection for early stage melanoma is often curative, but
metastatic disease carries a poor prognosis, highlighting
the importance of accurate staging. Whole-body positron
emission tomography (PET) with 2-[fluorine-18]-fluoro-2-
deoxy-D-glucose (FDG) combined with computed tomog-
raphy (CT) scans demonstrate improved sensitivity and
specificity for melanoma detection, and their utility in
melanoma staging and monitoring is well established
[1–5]. As systemic treatments for melanoma have
advanced, there has been increasing interest in using
FDG avidity not only for staging and monitoring, but
as a predictive biomarker to assess prognosis and ef-
fectiveness of therapy [6].
We present a case of increased FDG uptake in lymphoid
tissue as a surrogate marker of immune activation in a pa-
tient with metastatic melanoma treated with combination
ipilimumab and nivolumab, following non-response to
pembrolizumab monotherapy. Our discussion includes
details of radiographic imaging and pathologic analyses.
Case presentation
A 63-year-old man came to the University of California,
San Francisco in May 2015 seeking care for his
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melanoma. Review of outside medical records revealed
that in August 2014, a biopsy of a left scalp lesion
showed a non-ulcerated, 1.3 mm thick melanoma. He
subsequently underwent wide local excision (WLE) and
sentinel lymph node biopsy (SLNB). The SLNB was
positive for a 4 mm focus of BRAF wild-type melanoma
in the subcapsular region of a left cervical lymph node.
A PET/CT scan did not show any metastatic lesions.
During his consultation at UCSF, the initial diagnosis
of stage IIIA melanoma was confirmed. Unfortunately,
in the interim he had developed new hyperpigmented
papules on his left chest. One was biopsied on 5/19/15,
and pathology demonstrated features of epidermotropic
metastatic melanoma. He was upstaged to stage IV mel-
anoma, and on 7/1/15 was started on a clinical trial of
intralesional IL-12. He had progressive lesions after
12 weeks on therapy, and on 9/15/15 was transitioned to
standard of care pembrolizumab. He received two doses
(10/5/15, 10/26/15) which were well tolerated, but had
rapidly increasing size and number of hyperpigmented
papules and plaques across his chest, bilateral arms and
back. On 11/16/15 he received his first dose of combin-
ation ipilimumab/nivolumab. A PET/CT scan on 11/20/
15 did not show any lesions concerning for metastasis.
He went on to receive four induction doses of ipilimu-
mab/nivolumab; a PET/CT scan was repeated on 2/11/
16 and he was transitioned to nivolumab monotherapy.
At this time, the patient remains on nivolumab and is
tolerating treatment well.
Methods
Radiologic technique
Patient’s fasting time was at least six hours. Following
intravenous administration of F18-FDG, CT was acquired
from vertex to toes with intravenous contrast (Omnipaque
350), followed by an emission PET scan. A rotating 3D
maximum intensity projection image, as well as axial, cor-
onal, and sagittal PET images were interpreted.
Diagnostic dermatopathology
Punch biopsies of cutaneous chest lesions were obtained
prior to and during immunotherapy. Immunohistochemi-
cal staining was performed with antibodies against Melan-
A (clone A103; dilution 1:200) (Dako, Carpinteria, CA).
Diagnostic fine needle aspiration
Inguinal lymph nodes were visualized with ultrasound
imaging. Targets were oriented in a position that allowed
sampling throughout the hypoechoic cortex. On-site
smear evaluation showed adequate material.
Results
Clinical findings
The patient had widespread cutaneous metastases that
were readily clinically observed though not detected
on PET/CT. His photograph on 10/5/15, prior to
pembrolizumab, shows hyperpigmented papules scat-
tered on the chest and neck (Fig. 1a). While receiving
pembrolizumab, he developed increasing confluence
of existing chest papules, and numerous new hyper-
pigmented papules on the neck, abdomen and bilat-
eral upper arms. His treatment was changed to
ipilimumab/nivolumab on 11/16/15 due to clinical
concern for progressive disease. Upon completion of
ipilimumab/nivolumab induction, clinical photographs
were repeated on 2/23/16 (Fig. 1b). Although his ap-
pearance continued to be concerning for progression,
there were subtle improvements (absence of new
lesions, flattening papules) towards the end of the in-
duction period.
Radiologic findings
The PET/CT on 11/20/15, four days after the first dose of
ipilimumab/nivolumab, showed no remarkable areas of
FDG avidity (Fig. 2a). The PET/CT on 2/11/16 showed
hypermetabolic lymph nodes throughout multiple nodal
stations: in bilateral inguinal, iliac, and axillary lymph
Fig. 1 Clinical photographs prior to and during treatment with immune checkpoint inhibition. Panel a shows a photograph of the chest from
10/5/15 prior to initiation of pembrolizumab, with numerous hyperpigmented papules and plaques scattered across the chest. Panel b shows
a photograph of the chest from 2/23/16, after completing ipilimumab/nivolumab induction. There is increased confluence of existing lesions, as
well as new hyperpigmented papules on the bilateral upper arms and the neck
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nodes as well as in the spleen (Fig. 2b). The inguinal
lymph nodes were the largest, measuring 8 mm in short
axis, and with increased FDG avidity (12 SUVmax). There
was initial concern for progressive disease, however the
bilateral pattern of uptake, preservation of fatty hilum,
and concurrent splenic hypermetabolism (8.4 SUV max)
combined with clinically slowed growth and flattening of
cutaneous lesions were suggestive of FDG avidity as a
marker of immune activation rather than progressive
disease.
Pathologic findings
The skin biopsy on 5/19/15, prior to pembrolizumab
therapy, revealed a narrow diameter compound prolifer-
ation of melanocytes (Fig. 3a). There were nests of mela-
nocytes within the lower epidermis and scattered single
melanocytes in irregular pagetoid array above the basal
layer of the epidermis. There were similar melanocytes
in the dermis, and mitotic figures were evident among
the dermal melanocytes (Fig. 3b). The melanocytes in
the dermis generally did not diminish in size with des-
cent. These findings were consistent with epidermo-
trophic metastatic melanoma.
A punch biopsy was obtained of cutaneous lesions on
the right chest on 2/18/16, which showed melanophages
and fibrosis. A Melan-A immunostain confirmed that no
melanocytes were present in the dermis. These features
were consistent with complete regression of melanoma
(Fig. 3c, d).
Fine needle aspiration of bilateral inguinal lymph
nodes was done on 2/17/16. Pathology yielded unre-
markable small lymphocytes, without evidence of malig-
nancy [7, 8] (Fig. 3e).
Conclusions
Monoclonal antibodies against PD-1 and CTLA-4 are
approved for advanced melanoma, non-small cell lung
cancer, and renal cell carcinoma, and are being investi-
gated in numerous other cancers. Use of immunother-
apies is poised to increase in the coming years, thus
highlighting the need for clinicians to gain expertise in
immunotherapeutic response patterns.
Historically, the Response Evaluation Criteria in
Solid Tumors (RECIST) have been the most widely
accepted guidelines for defining solid tumor progres-
sion [9, 10]. However, atypical response patterns have
been demonstrated in clinical trials of ipilimumab
[11] and pembrolizumab [12], and have led to the
development of immune-related response criteria
(irRC) [11]. Described patterns of atypical response,
or pseudoprogression, have included initial increases
in the size of target lesions followed by decreases
without the appearance of new lesions, and regres-
sion of target lesions but with appearance of new
lesions. Benign lymphadenopathy has also been de-
scribed as a radiographic finding in melanoma pa-
tients treated with anti-CTLA-4 therapy, the most
common pattern reported to be sarcoid-like and in a
bilateral hilar and mediastinal distribution. These
findings were seen in a series of eight patients on
anti-CTLA-4 therapy; there was no reported detail
on FDG avidity. Interestingly, in the same series,
radiologic evidence of immune-related effects seemed
to correlate with response to treatment [13]. More
recent efforts to identify an imaging biomarker have
reported an elevated spleen-to-liver SUV ratio to be
associated with increased overall survival in meta-
static melanoma patients treated with anti-CTLA-4
or anti-PD-1 therapy [14].
Our case is the first report of FDG-avid diffuse
lymphadenopathy occurring with combined CTLA-4
and PD-1 blockade, with correlative pathology con-
firming benign lymphadenopathy and regression of
a b
Fig. 2 Maximum intensity projection images of two whole-body
18 F-FDG PET/CT studies. Panel a shows the PETCT from 11/20/15,
early in the course of immunotherapy. Panel b shows the PET/CT
from 2/11/16, after completion of induction ipilimumab/nivolumab.
Arrows indicate the increased metabolic glucose consumption in
bilateral inguinal, iliac, axillary lymph nodes as well as the spleen,
highly suggestive of immune activation
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cutaneous metastases. The initial clinical impression
of disease progression proved to be erroneous after
assiduous review of radiographic imaging and biopsy
results. This highlights the importance of multi-
disciplinary evaluation of these cases, and the need
for more prospective work to evaluate FDG avidity of
benign lymphoid tissue in a larger case series as a
surrogate for clinical benefit [15]. Heightened aware-
ness of the full spectrum of benign findings and atyp-
ical response patterns seen with immunotherapies will
improve our care of cancer patients being treated
with these increasingly widespread agents, and en-
courage further research and development of novel
imaging biomarkers.
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